Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...8889909192939495969798...858859»
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Trial completion date, Trial primary completion date:  REVERT: REVErsing Airway Remodelling With Tezepelumab (clinicaltrials.gov) -  Mar 2, 2024   
    P3,  N=90, Recruiting, 
    Trial primary completion date: Aug 2024 --> Aug 2025 Trial completion date: Mar 2025 --> Jun 2026 | Trial primary completion date: Mar 2025 --> Dec 2025
  • ||||||||||  daxdilimab (HZN-7734) / Amgen
    Trial completion date, Trial termination, Trial primary completion date:  Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN) (clinicaltrials.gov) -  Mar 2, 2024   
    P2,  N=19, Terminated, 
    Trial completion date: Mar 2025 --> Jun 2026 | Trial primary completion date: Mar 2025 --> Dec 2025 Trial completion date: Nov 2026 --> Jan 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2025 --> Jan 2024; Sponsor Decision
  • ||||||||||  AMG 193 / Amgen
    Trial completion date, Trial primary completion date:  A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors (clinicaltrials.gov) -  Mar 2, 2024   
    P1/2,  N=527, Recruiting, 
    Trial completion date: Apr 2024 --> Oct 2025 | Trial primary completion date: Apr 2024 --> Sep 2025 Trial completion date: Feb 2028 --> Mar 2029 | Trial primary completion date: Feb 2026 --> Nov 2027
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    Trial completion date, Trial primary completion date:  DeLLphi-301: A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) -  Mar 2, 2024   
    P2,  N=222, Active, not recruiting, 
    Trial completion date: Feb 2028 --> Mar 2029 | Trial primary completion date: Feb 2026 --> Nov 2027 Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Feb 2024 --> Oct 2024
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Trial completion date:  Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma (clinicaltrials.gov) -  Mar 2, 2024   
    P3,  N=107, Active, not recruiting, 
    Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025 Trial completion date: Jan 2024 --> Jan 2025
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Treatment of Medication-Related Osteonecrosis of the Jaws without Segmental Resections: A Case Series. (Pubmed Central) -  Mar 1, 2024   
    There was complete resolution of disease in all patients, with only 1 relapse. CONCLUSIONS This case series suggests that it is possible to treat MRONJ with conservative therapies in the early stages of the disease and minimally invasive surgeries in more advanced stages of the disease, thus avoiding segmental jaw resections.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Review, Journal:  Approach to Older Adults With Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia. (Pubmed Central) -  Mar 1, 2024   
    T-cell ALL remains an area of unmet need and effort is required to ensure that therapeutic advances benefit all populations equitably. In this manuscript, we review current data and ongoing trials regarding the treatment of older adults with Ph-neg ALL and define topics for further research.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Treatment of Osteoporosis after Hip Fracture: Survey of the Korean Hip Society. (Pubmed Central) -  Feb 29, 2024   
    Denosumab was the most commonly used first-line treatment option for osteoporosis in hip fracture patients...The results of this study that surveyed orthopedic hip surgeons showed that most participants followed the current strategy for management of osteoporosis. Because the end result of osteoporosis is a bone fracture, active involvement of orthopedic surgeons is important in treating this condition.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal, Real-world evidence, Real-world effectiveness, Real-world:  Real-world effectiveness of erenumab in Japanese patients with migraine. (Pubmed Central) -  Feb 29, 2024   
    Erenumab was effective in migraine patients. At least 4-6 months may be preferable for efficacy evaluation in patients switching to erenumab from other CGRP mAbs.
  • ||||||||||  Olumiant (baricitinib) / Eli Lilly
    Phase classification:  RA-BRANCH: A Study of Baricitinib in Participants With Rheumatoid Arthritis (clinicaltrials.gov) -  Feb 29, 2024   
    P4,  N=1300, Recruiting, 
    At least 4-6 months may be preferable for efficacy evaluation in patients switching to erenumab from other CGRP mAbs. Phase classification: P3b/4 --> P4
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    neoBCC  (Amphith) -  Feb 28, 2024 - Abstract #EADO2024EADO_204;    
  • ||||||||||  ivabradine / Generic mfg.
    Review, Journal:  Clinical Implications of Ivabradine in the Contemporary Era. (Pubmed Central) -  Feb 28, 2024   
    An important fact yet to be explored is the clinical applicability of ivabradine in patients with atrial fibrillation, a concern that beckons future investigation. In this review, the concept of overlap theory it introduced, along with its application to expand the indication of ivabradine and the overlap theory-guided optimal ivabradine therapy.
  • ||||||||||  verapamil / Generic mfg., flecainide / Generic mfg., ivabradine / Generic mfg.
    Journal:  HRAS-Mutant Cardiomyocyte Model of Multifocal Atrial Tachycardia. (Pubmed Central) -  Feb 28, 2024   
    CS-associated gain-of-function HRASG12 mutations in induced pluripotent stem cells-derived ACMs trigger transcriptional changes associated with enhanced automaticity and arrhythmic activity consistent with multifocal atrial tachycardia. This is the first human-induced pluripotent stem cell model establishing the mechanistic basis for multifocal atrial tachycardia in CS.
  • ||||||||||  Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
    Enrollment closed, Trial completion date, Trial primary completion date:  STARA: Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis (clinicaltrials.gov) -  Feb 28, 2024   
    P4,  N=290, Active, not recruiting, 
    This is the first human-induced pluripotent stem cell model establishing the mechanistic basis for multifocal atrial tachycardia in CS. Unknown status --> Active, not recruiting | Trial completion date: Aug 2020 --> Aug 2024 | Trial primary completion date: Jun 2020 --> Jun 2024
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Stivarga (regorafenib) / Bayer, sunitinib / Generic mfg.
    Enrollment open, Stroma:  Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor (clinicaltrials.gov) -  Feb 28, 2024   
    P2,  N=48, Recruiting, 
    Taken together, DUB3 is a MAGEA3 deubiquitinase, and abrogating DUB3 enzymatic activity by palbociclib is a promising therapeutic strategy for HCC. Not yet recruiting --> Recruiting
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Enrollment change, Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world:  ASCENT: A Study for Observing Severe Asthma in Patients Treated With Tezepelumab (clinicaltrials.gov) -  Feb 28, 2024   
    P=N/A,  N=550, Recruiting, 
    Not yet recruiting --> Recruiting N=200 --> 550 | Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Dec 2024 --> Nov 2025
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene, Stivarga (regorafenib) / Bayer, Sutent (sunitinib) / Pfizer
    Journal, Adverse events:  Integrating network pharmacology and drug side-effect data to explore mechanism of liver injury-induced by tyrosine kinase inhibitors. (Pubmed Central) -  Feb 28, 2024   
    Based on the target prediction results of drugs and reactive metabolites, we also shed light on the association between toxic metabolites and severe hepatic adverse reactions, and thinking HSPA8, HSPA1A, CYP1A1, CYP1A2 and CYP3A4 were potential therapeutic or preventive targets against TKI-induced liver injury. In conclusion, our research provides comprehensive insights into the mechanism underlying severe liver injury caused by TKIs, offering a better understanding of how to enhance patient safety and treatment efficacy.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, reparixin (DF 1681Y) / Dompe
    Journal:  The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast. (Pubmed Central) -  Feb 27, 2024   
    Golimumab achieves a satisfying injection experience and relieves the level of ISRs over etanercept in patients with rheumatic diseases. Taken together, our study implicates CXCL1 as a critical role in ERBC growth and metastasis via crosstalk with fibroblast and cotargeting CXCR1/2 and CDK4/6 could potentially overcome endocrine resistant breast cancer.
  • ||||||||||  Stivarga (regorafenib) / Bayer, Sutent (sunitinib) / Pfizer
    Review, Journal:  Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma. (Pubmed Central) -  Feb 27, 2024   
    Indeed, despite the best treatments available including surgery, radiotherapy or a pharmacological approach with Temozolomide, glioblastoma patients' mortality is still high, within a few months of diagnosis...In the past, efforts to treat glioblastoma have mostly concentrated on customized treatment plans that target specific mutations such as epidermal growth factor receptor (EGFR) mutations, Neurotrophic Tyrosine Receptor Kinase (NTRK) fusions, or multiple receptors using multi-kinase inhibitors like Sunitinib and Regorafenib, with varying degrees of success...Activated AXL leads to a significant increase in tumor proliferation, tumor cell migration, and angiogenesis in different in vitro and in vivo models of cancer since this receptor regulates interplay with apoptotic, angiogenic and inflammatory pathways. Based on these premises, in this review we mainly focused on the role of AXL in the course of glioblastoma, considering its primary biological mechanisms and as a possible target for the application of the most recent treatments.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
    Journal, Metastases:  Delphi consensus for the third-line treatment of metastatic colorectal cancer. (Pubmed Central) -  Feb 27, 2024   
    Based on these premises, in this review we mainly focused on the role of AXL in the course of glioblastoma, considering its primary biological mechanisms and as a possible target for the application of the most recent treatments. The experts agreed with most of the proposed items on 3L treatment of mCRC, prioritizing therapeutic options that increase survival and preserve QoL, while facilitating the possibility that patients can continue to be treated later.